Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term follow-up study of HZ/su vaccine efficacy, safety, and immune persistence after ZOSTER-006/022
2021-005319-30Phase 3Active
- Sponsor
- GSK
- Start
- May 2022
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of Zoster vaccine recombinant in herpes zoster (HZ) (3 arms), sponsored by GSK. Primary endpoint: Number of participants in LTFU and Control groups with confirmed herpes zoster cases. Started May 2022; status: active.
02
Drugs
Zoster vaccine recombinant
03
Conditions
herpes zoster (HZ)
Beyond the preview
Go deeper on 2021-005319-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005319-30.